Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2678649 | Pediatria Polska | 2016 | 6 Pages |
Abstract
Cyclosporin A is an immunosuppressive cyclic peptide. It has not only been a milestone in a transplantology, but is also a treatment's option in gastrology and hepatology. Cyclosporin A primarily affects T lymphocytes activation and proliferation through a calcineurin inhibition. Cyclosporin's A pharmacokinetic features force a dose modification based on its blood concentration and expected therapeutic level. The most frequent adverse effects are renal function impairment, hypertension, and hirsutism. CsA is metabolized mainly in the liver by cytochrome P450 enzymes, hence many drug interactions may occur. Although CsA presents variable bioavailability and poses a threat of adverse effects development, it induces remission in refractory paediatric ulcerative colitis and autoimmune hepatitis.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Marcin Osiecki, MaÅgorzata Woźniak, JarosÅaw KierkuÅ,